Approved prescription drug
Its specific FDA approval and labeling matter. A clinic still needs qualified prescribers and lawful handling.
Product-category checkpoint
Do not turn research-use peptides into a clinic treatment plan
A product description, wholesale catalog or disclaimer does not establish a lawful patient-care route. Before a clinic plans to offer treatment, qualified clinical and legal reviewers must verify the exact product, channel and state requirements.
Keep categories distinct
Compounded medication
Compounding is subject to its own federal and state conditions and is not simply the same as an approved drug. Rules and supply status can change.
Research-use material
A "not for human use" label is not a shortcut to market the material for human treatment. Do not represent this category as patient-care supply.
Unverified product
Unknown identity, claims or route means stop. Record the question and have a qualified reviewer check it.
What the clinic should ask before planning any offering
- What exact product and proposed use is being considered? Do not make an efficacy claim without evidence and review.
- What federal and state rules apply now to the product, professional scope, sourcing, handling and advertising?
- Which qualified clinician and counsel will own those decisions?
- What operational work remains if the route is verified, and what is the pause plan if it is not?
FDA warning letters describe cases where sellers' research-use labels conflicted with marketing that suggested human use. FDA has also clarified evolving GLP-1 compounding policies as national supply stabilized. Neither source gives a blanket answer for a clinic's future service or named supplier.
This page does not recommend any product or supplier, identify a lawful patient use, or provide dosing advice. An optional supplier assessment in the course happens only after individualized review and could conclude that no suitable route exists.
Primary sources to recheck
- FDA warning letter to Peptide Partners LLC, August 2026: an enforcement example about product marketing.
- FDA GLP-1 compounding policy update: check current status and conditions, not an old summary.
- FTC Health Products Compliance Guidance: substantiation of health-related advertising claims.
Reviewed September 26, 2026. Qualified review of the exact clinic and then-current law is required.
Return to the readiness checklist · Compare the business-education tiers